imatinib mesylate has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
AlAsfoor, S; Bosch, AJT; Calabrese, D; Cavelti-Weder, C; Dervos, T; Matter, MS; Rohm, TV; Weber, A | 1 |
Kim, DH; Kim, J; Kwon, JS; Lee, JW; Lee, S; Lee, SK; Sandhu, J; Tontonoz, P | 1 |
2 other study(ies) available for imatinib mesylate and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver.
Topics: Adipose Tissue; Animals; Gene Expression Regulation; Humans; Imatinib Mesylate; Inflammation; Lipogenesis; Liver; Macrophages; Male; Mice, Inbred C57BL; Monocytes; Non-alcoholic Fatty Liver Disease; Obesity; Protein Kinase Inhibitors; Signal Transduction; Sterol Regulatory Element Binding Proteins; Tumor Necrosis Factor-alpha | 2018 |
Critical Roles of the Histone Methyltransferase MLL4/KMT2D in Murine Hepatic Steatosis Directed by ABL1 and PPARĪ³2.
Topics: Animals; Diet, High-Fat; Histone-Lysine N-Methyltransferase; Imatinib Mesylate; Liver; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; PPAR gamma; Protein Binding; Proto-Oncogene Proteins c-abl; Response Elements; Transcriptional Activation; Transcriptome | 2016 |